Provectus Biopharmaceuticals Inc (PVCT)

[Paulness]

Provectus is a clinical-stage biotechnology company developing immunotherapy
medicines based on an entire, wholly-owned family of chemical small molecules
called halogenated xanthenes. The Company's proprietary lead molecule is cGMP
RBD. IL PV-10, the first small molecule autolytic immunotherapy and a
formulation of cGMP RBD, can induce immunogenic cell death ("ICD"), and is
undergoing clinical study for adult solid tumor cancers, such as melanoma and GI
tumors (e.g., HCC, mCRC, mNET, mUM), and preclinical study for pediatric solid
tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma,
osteosarcoma). Topically-administered PH-10, an immune-modulatory agent and
formulation of cGMP RBD, is undergoing clinical study for inflammatory
dermatoses (e.g., psoriasis, atopic dermatitis). New systemically-administered
formulations of cGMP RBD are being investigated for hematology (e.g., acute
myeloid leukemia, acute monocytic leukemia) and virology (e.g., SARS-CoV-2).